WO1998046640A3 - Methods and compositions for inducing immunosuppression - Google Patents

Methods and compositions for inducing immunosuppression Download PDF

Info

Publication number
WO1998046640A3
WO1998046640A3 PCT/US1998/007557 US9807557W WO9846640A3 WO 1998046640 A3 WO1998046640 A3 WO 1998046640A3 US 9807557 W US9807557 W US 9807557W WO 9846640 A3 WO9846640 A3 WO 9846640A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
useful
pbls
inducing
immunosuppression
Prior art date
Application number
PCT/US1998/007557
Other languages
French (fr)
Other versions
WO1998046640A2 (en
Inventor
Cynthia G Healy
Wade E Bolton
Jonathan Wilson Simons
Original Assignee
Coulter Int Corp
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coulter Int Corp, Univ Johns Hopkins filed Critical Coulter Int Corp
Publication of WO1998046640A2 publication Critical patent/WO1998046640A2/en
Publication of WO1998046640A3 publication Critical patent/WO1998046640A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A proteinaceous composition isolated from the serum of a human having prostate cancer and having a molecular weight of approximately 105,000 to 112,000 daltons, as determined by SDS polyacrylamide gel electrophoresis, has the ability to induce immunosuppression in a culture of normal human peripheral blood lymphocytes (PBLs). This composition, and the polypeptide isolated therefrom, reduces the activation/proliferation response of normal donor PBLs, by inducing an alteration in the expression of the signal transducer, TCR-z. Detection and measurement of this immunosuppressive composition in a subject's PBLs can indicate immune dysfunction or a change in the immune status following treatment, e.g., chemotherapeutic treatment. This immunosuppressive composition or components isolated therefrom are useful in therapeutic methods for inducing immunosuppression, where desired. This composition is also useful to induce an immune response in a subject to the presence of the immmunosuppressive component on the surface of a cancer cell. Thus, this composition is useful in vaccines and as a diagnostic agent.
PCT/US1998/007557 1997-04-15 1998-04-15 Methods and compositions for inducing immunosuppression WO1998046640A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83418197A 1997-04-15 1997-04-15
US08/834,181 1997-04-15

Publications (2)

Publication Number Publication Date
WO1998046640A2 WO1998046640A2 (en) 1998-10-22
WO1998046640A3 true WO1998046640A3 (en) 1999-01-21

Family

ID=25266296

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007557 WO1998046640A2 (en) 1997-04-15 1998-04-15 Methods and compositions for inducing immunosuppression

Country Status (1)

Country Link
WO (1) WO1998046640A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828302B1 (en) 1999-12-08 2004-12-07 Xcyte Therapies, Inc. Therapeutic uses of depsipeptides and congeners thereof
EP1438966B1 (en) 1999-12-08 2007-02-14 Cyclacel Pharmaceuticals, Inc. Use of depsipeptide and congeners thereof as immunosuppressants for treating an infectious disease, an autoimmune disease, allergic reactions or a hyperproliferative skin disease.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004421A1 (en) * 1984-03-23 1985-10-10 Sandoz Ag Immunosuppressant factor
WO1993019605A1 (en) * 1992-04-06 1993-10-14 Ochoa Augusto C Evaluation and treatment of patients with progressive immunosuppression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004421A1 (en) * 1984-03-23 1985-10-10 Sandoz Ag Immunosuppressant factor
WO1993019605A1 (en) * 1992-04-06 1993-10-14 Ochoa Augusto C Evaluation and treatment of patients with progressive immunosuppression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ABLIN R J: "Serum proteins in prostatic cancer VI. Reduction of the suppressive ("blocking"?) properties of serum on in vitro parameters of cell-mediated immunologic responsiveness following cryosurgery.", UROLOGIA INTERNATIONALIS, (1977) 32 (1) 65-73. JOURNAL CODE: WRI. ISSN: 0042-1138., Switzerland, XP002083462 *
EBERT E. ET AL: "Characterization of an immunosuppressive factor derived from colon cancer cells", JOURNAL OF IMMUNOLOGY, vol. 138, 1987, pages 2161 - 2168, XP002083459 *
TAMURA K ET AL: "Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients.", CANCER RESEARCH, (1981 AUG) 41 (8) 3244-52. JOURNAL CODE: CNF. ISSN: 0008-5472., United States, XP002083461 *
WHITEHEAD J.S. ET AL: "An inhibitor of lymphocyte proliferation produced by a human colonic adenicarcinoma cell line in culture", CANCER RESEARCH, vol. 40, 1980, pages 29-35, XP002083463 *

Also Published As

Publication number Publication date
WO1998046640A2 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
CA2178752A1 (en) N-Terminally Chemically Modified Protein Compositions and Methods
ES8506087A1 (en) Preparation of functional human urokinase polypeptides.
AU4094196A (en) Improvements in or relating to contrast agents
ATE87655T1 (en) MARKERS OF T-CELL ACTIVATION.
EP1005540A4 (en) Ikk-beta proteins, nucleic acids and methods
TR199802572T2 (en) Scanning methods for detecting compounds suitable for adjusting body weight.
CA2068204A1 (en) Latency associated peptides and uses therefor
WO1996019580A3 (en) Telomerase protein component
WO2001025438A3 (en) Ifn-alpha homologues
AU2236795A (en) Afamin: a human serum albumin-like protein
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
IL91184A0 (en) N-2,3-butadienyl tri-and tetraaminoalkane derivatives
AU8755591A (en) Gro genes, proteins, and uses thereof
WO1998046640A3 (en) Methods and compositions for inducing immunosuppression
AU1828388A (en) Promoters for the expression of foreign dna in methylotrophic bacteria, the obtaining thereof and the use thereof
WO1990007321A3 (en) Lymphocyte receptor homing sequences and their uses
CA2175476A1 (en) Opioid receptor: compositions and methods
AU4757393A (en) Modified platelet factor-4
AU3608589A (en) Expression vectors for the preparation of infused proteins in microorganisms
CA2139518A1 (en) Antigenic regions of tlp complexes and antibodies against the same
CA2112701A1 (en) Proteins s polypeptides and uses thereof
IT1283899B1 (en) PEPTIDES AND THEIR USES IN THE CELIAC DISEASE THERAPY
IL91771A0 (en) Increased expression of small molecular weight recombinant proteins
CA2163805A1 (en) Novel activating factor of leukocytes
Yusupova et al. Isolation and properties of phenylalanine aminopeptidase from Trichoderma koningii.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998544243

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase